Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for Arbutus Biopharma Corp Common Shares (ABUS).
- Disclosed ownership: 14%.
- Date of event: 31 Dec 2025.
MORGAN STANLEY - 31 Dec 2025 SCHEDULE 13G/A Report for Arbutus Biopharma Corp Common Shares (ABUS)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Security
- Arbutus Biopharma Corp Common Shares
- Symbol
- ABUS
- Shares outstanding
- 191,928,422 shares
- Disclosed Ownership
- 25,910,337 shares
- Ownership
- 14%
- Form type
- SCHEDULE 13G/A
- Filing time
- 11 Feb 2026, 13:45:46 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 03 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 14% ownership in Arbutus Biopharma Corp Common Shares (ABUS) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 03 Feb 2025.
- Current filing was accepted on 11 Feb 2026, 13:45.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 14% | 25,910,337 | 0 | 25,899,506 | Chris O'Hara | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley Investment Management Inc. | 13% | 25,647,127 | 0 | 25,647,127 | Deidre A. Downes | Authorized Signatory, Morgan Stanley Investment Management Inc. |